BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

Core Insights - BioCryst Pharmaceuticals has completed the acquisition of Astria Therapeutics, enhancing its leadership in hereditary angioedema (HAE) and supporting long-term growth [1][5] Acquisition Details - The acquisition was valued at approximately $700 million, financed through cash on hand and a financing facility, with BioCryst issuing about 37.3 million shares to Astria's equity holders [5] Product Portfolio Enhancement - BioCryst adds navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 development, which could be the first HAE therapy with every-three and every-six month dosing, improving patient treatment experiences [2][3] - The company now offers both the leading oral therapy (ORLADEYO®) and a potentially best-in-class injectable option, providing optimal choices for individualized patient care [3] Strategic Leadership Changes - Jill C. Milne, Ph.D., co-founder and CEO of Astria, has joined BioCryst's Board of Directors, while John Ruesch has been appointed as Chief Technical Operations Officer, bringing expertise in product development [6] Additional Programs - BioCryst has acquired Astria's early-stage program for atopic dermatitis, STAR0310, and plans to explore strategic alternatives for this program [4]